The Function Role of miR-181a in Chemosensitivity to Adriamycin by Targeting Bcl-2 in Low-Invasive Breast Cancer Cells

Ying Zhu\textsuperscript{a,b} Jianzhong Wu\textsuperscript{b} Shuchun Li\textsuperscript{c} Rong Ma\textsuperscript{b} Haixia Cao\textsuperscript{b} Minghua Ji\textsuperscript{d} Changwen Jing\textsuperscript{b} Jinhai Tang\textsuperscript{a}

\textsuperscript{a}Department of General Surgery, the Affiliated Jiangsu Cancer Hospital, Nanjing Medical University, \textsuperscript{b}Research Center of Clinical Oncology, the Affiliated Jiangsu Cancer Hospital, Nanjing Medical University, \textsuperscript{c}School of Pharmaceutical science, Nanjing University of Technology, \textsuperscript{d}Department of Radiotherapy, the Affiliated Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing, Jiangsu, P.R. China

Key Words
miR-181a \• Breast cancer \• Chemosensitivity \• Adriamycin \• Bcl-2

Abstract

Objectives: miR-181a is involved in immunity, metabolism, tumor suppression or carcinogenesis reported by many other studies. However, its role in the development of chemosensitivity to adriamycin in low-invasive breast cancer cells remains unclear. The aim of this study is to define the function role of miR-181a in promoting the efficacy of adriamycin-based neoadjuvant chemotherapy.

Methods: Cell survival analysis was detected by Cell Counting Kit-8 assay. Apoptotic cells were quantitatively detected using FITC Annexin V apoptosis Detection Kit I. Bcl-2 protein expression was measured by western blot. Luciferase reporter vector with the putative BCL-2 3’ untranslated region (3’UTR) was constructed to explore whether BCL-2 was a direct target gene of miR-181a. Real-time PCR was performed to test the expression of miR-181a and Bcl-2 in the selected breast cancer tissue samples.

Results: The down-regulation of miR-181a decreased adriamycin-induced apoptosis in MCF-7 cells. Transfected with miR-181a mimic in cells resulted in the decreased expression of Bcl-2. The alteration of miR-181a expression did not significantly affect the chemosensitivity to adriamycin in MCF-7 and MCF-7/ADR cells with genetic knockout of Bcl-2. miR-181a may suppress Bcl-2 expression by forming imperfect base pairing with the 3’UTR of Bcl-2 gene such that a negative relationship between miR-181a and Bcl-2 in MCF-7 and MCF-7/ADR cells is observed.

Conclusions: At least in part, the detection of miR-181a may direct the clinical medication in patients with neoadjuvant chemotherapy because of miR-181a enhanced adriamycin-induced apoptosis via targeting Bcl-2.
Introduction

Breast cancer (BC) is a health-threatening disease of great magnitude among women around the world. Breast cancer-related outcomes, including an increasing incidence and decreasing mortality, are due to effectively early diagnosis and the standardized existing treatments [1]. Traditionally, a definitive surgical procedure is one of the fundamental treatment in BC. Few patients present with unresectable, locally advanced disease and require the systemic treatment [2, 3]. Thus, designated chemotherapy is used to diminish the volume of tumor or prolong the survival period of these patients.

Currently, several microRNAs have been investigated for their expression in tumourigenesis to discover the possible role in pathogenesis and evaluate their use for diagnosis and prognosis of some cancers [4-8]. Only a few of studies [9-16] are investigating the involvement of miR-181a in chemosensitivity in various disorders. B. Zhou et al. showed that miR-181a regulated SIRT1 and improved hepatic insulin sensitivity. Decreased miR-181a might be a potential new strategy for treating insulin resistance and type 2 diabetes [9]. It also facilitated Growth Factor Signaling in tamoxifen-resistant breast cancer by down-regulating TIMP3 [14]. Consistent with our hypothesis, miR-181a sensitized K562/A02 and SGC7901/VCR cell lines by targeting Bcl-2 [15, 16]. Currently, 28 target genes of hsa-miR-181a have been validated [10-12, 17, 18]. The presence of many matching sites between the mature miR-181a seed region have facilitated the role of miR-181a in chemotherapy, giving them access to the modulation of a huge number of cellular pathways, especially apoptosis or anti-apoptosis ones.

MCF-7(ER+, PgR+,HER2-) is one of the most representative low-invasive breast cancer cells treatment by adriamycin. Our study identified that miR-181a played an important role in chemosensitivity to adriamycin in MCF-7 and MCF-7/ADR cells via targeting Bcl-2. miR-181a-based therapy might be a potential new strategy for low-invasive breast cancer patients with poor-response to adriamycin.

Materials and Methods

Cell Culture

Human breast cancer cell line MCF-7 and its resistant MCF-7/ADR were obtained from ATCC (Rockville, MD). Cells were cultured in DMEM supplemented (Gibco, Grand Island, NY, USA) with 10% fetal bovine serum (Gibco) in a humidified atmosphere of 5% CO₂ at 37℃.

Cell transfection

Hsa-miR-181a mimic, hsa-miR-181a inhibitor and hsa-miR negative control were synthesized by Genepharma (Shanghai, China, showed in Table 1). Small inhibitory RNA (siRNA) to Bcl-2 and SignalSilence® Control siRNA were purchased from Cell Signaling Technology. Twenty-four hours prior to transfection, MCF-7 and MCF-7/ADR cells were plated in 6-well plates (2.5×10⁵ cell/well) and then transfected with miR-181a mimic (50nM) or miR-181a inhibitor (50nM) or miR negative control (50nM) using Lipo2000 (Invitrogen, Carlsbad, CA). 100nM SignalSilence® Control siRNA or SignalSilence® Bcl-2 siRNA were transfected into cells following the manufacturer’s protocol.

Cell Survival Analysis

Twenty-four hour post-transfection, cells were seeded into 96-well plates (6×10³/well) and treated with ADR (Hisun Pharmaceutical Co., Zhejiang, China) at different concentration for 48h. The Cell Counting Kit-8 assay (Dojindo, Kumamoto Prefecture, Kyushu, Japan) was used to determine relative cell growth according to the manufacturer’s instructions. Data shown are representative of three independent experiments.

Apoptosis assay

MCF-7/ADR and MCF-7 cells were transfected with miR-181a mimic and miR-181a inhibitor for 48 hours and incubated with 20mg/L ADR or 0.2mg/L ADR for 48 hours, respectively. Then,
1×10⁶ cells were collected and washed twice with ice-cold PBS. Cells were dual stained using FITC Annexin V apoptosis Detection Kit I (BD Biosciences, Franklin Lakes, NJ) according to the manufacturer’s protocol. Stained cells were immediately analyzed using a flow cytometer (BD Biosciences).

**Real-time PCR assays**

Total RNA was extracted by Trizol (Invitrogen, Carlsbad, CA) and subjected to reverse transcription using TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions. For detection of mature miRNAs, the TaqMan® microRNA Assay (Applied Biosystems, Foster City, CA) was used according to the manufacturer’s instructions. The quantitative analysis of the change in expression levels was calculated by ABI 7300 real-time PCR machine (Applied Biosystems, Carlsbad, CA). An average of three experiments each performed in triplicate with standard errors is presented. Primer quality was analyzed by dissociation curves. Primer sequences are listed in Table 1. Data were analyzed by comparing Ct values.

**miRNA Target Gene Identification**

For miRNA target gene identification, TargetScan (http://www.targetscan.org) and miRecord (http://mirecords.biolead.org) were used to identify target genes of identified miRNAs.

**Dual Luciferase Activity Assay**

The 3'UTR of human Bcl-2 cDNA containing the putative target site for the mature miR-181a was chemically synthesized and inserted at the XbaI site. MCF-7 cells (6×10⁴/well) were incubated in 24-well plates and co-transfected with miR-181a mimic or control mimic and PGL3-Bcl-2 3'UTR-WT vector or PGL3-Bcl-2 3'UTR-MUT vector containing firefly luciferase reporter gene and 3'UTR of Bcl-2 gene (Promega, Madison, WI) using lip2000 (Invitrogen, Carlsbad, CA). Luciferase activity was measured 48 hours after transfection using the Dual Luciferase Reporter Assay System (Promega) and normalized to renilla luciferase activity.

**Western blot**

Cells were extracted and prepared in modified RIPA buffer (Beyotime, Jiangsu, China). Proteins were separated by 10% SDS-PAGE, transferred to polyvinylene difluoride membranes (Bio-Rad, Hercules, CA) and incubated with primary antibodies against human Bcl-2 (1:500, Santa Cruz, CA) overnight at 4°C. The horseradish peroxidase-conjugated secondary antibody was from Dako Co, Denmark. Immunoreactive bands were visualized by chemiluminescence with Pierce ECL detection reagent (Millipore, Billerica, MA). β-actin (1:4000, Bioworld, MN) was used as an internal loading control. Shown are representative data from individual experiments that were repeated at least twice.

**Patients and Samples**

Samples were obtained from patients treated at the Jiangsu Cancer Hospital, Affiliated Hospital of Nanjing Medical University, from 2010-2012, comprising neoadjuvant chemotherapy (NAC) patients (n=35) and non-neoadjuvant chemotherapy patients (n=43) with non-metastatic disease at diagnosis. The
diagnosis of each case was confirmed independently by two pathologists based on WHO classification. In accordance with the following criteria: These NAC patients were to receive 2-6 cycles of preoperative neoadjuvant chemotherapy with FAC or AC (ADR 40 mg/m² and CTX 0.6 g/m² combined with or without 5-Fu 0.5g/m²) on day 1 with treatments repeated every 21 days; a histological diagnosis of invasive ductal or lobular carcinoma with at least one measurable lesion; a clinical stage of IIA-IIB; without triple negative breast cancer (TNBC) or HER-2 positive patients. According to the patient’s response assessed by computer tomography (CT) tests and detection of serum tumor marker. Tissue samples of NAC patients were classified into responders (complete reponse or partial reponse) and non-responders (stable disease or progressive disease). Therapy of other forty-three non-neoadjuvant chemotherapy patients consisted of breast conserving surgery or modified radical mastectomy without neoadjuvant therapy. The patients gave written informed consent in accordance with the Declaration of Helsinki and the study was approved by the Ethics Committee of the Jiangsu Cancer Hospital.

Table 2. Comparison of several clinicopathologic parameters and expression levels of miR-181a in Breast Cancer

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>miR-181a^a</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Median (25th-75th percentile in parenthesis) normalized by U6, log2 scale)</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 47</td>
<td>21</td>
<td>-3.501 (-5.964 -1.881)</td>
</tr>
<tr>
<td>&gt; 47</td>
<td>22</td>
<td>-2.735 (-4.124 -0.930)</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Histology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>invasive ductal carcinoma</td>
<td>35</td>
<td>-3.037 (-5.581 -0.998)</td>
</tr>
<tr>
<td>invasive lobular carcinoma</td>
<td>8</td>
<td>-2.745 (-4.571 -2.024)</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>34</td>
<td>-3.037 (-5.964 -0.994)</td>
</tr>
<tr>
<td>II</td>
<td>9</td>
<td>-2.595 (-4.094 -1.171)</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Tumor diameter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T &lt; 2cm</td>
<td>14</td>
<td>-3.037 (-6.629 -0.604)</td>
</tr>
<tr>
<td>T &gt; 2cm</td>
<td>29</td>
<td>-2.992 (-4.395 -1.224)</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Lymph node</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>24</td>
<td>-2.199 (-4.049 -0.565)</td>
</tr>
<tr>
<td>Positive</td>
<td>19</td>
<td>-3.138 (-8.224 -1.746)</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Her-2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>18</td>
<td>-2.957 (-4.596 -0.909)</td>
</tr>
<tr>
<td>Positive</td>
<td>25</td>
<td>-3.806 (-5.964 -2.099)</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Ki-67</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>19</td>
<td>-2.417 (-5.391 -0.65)</td>
</tr>
<tr>
<td>Positive</td>
<td>24</td>
<td>-2.921 (-4.541 -1.29)</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td>&gt; 0.05</td>
</tr>
</tbody>
</table>

^aMedian of relative expression, with 25th-75th percentile in parenthesis normalized by U6, log2 scale; ^bMann-Whitney U test between two groups.
Statistical Analysis

The results presented are average of at least three experiments each performed in triplicate with standard errors. Statistical analyses were performed by analysis of variance, followed by Kruskal-Wallis test or Spearman rank test, using SPSS 20.0 statistical package. All test were two tailed; \( p < 0.05 \) were considered significant and are indicated with asterisks.

Results

Expression of miR-181a in human breast cancer specimens

The aberrant expression in breast cancer prompted us to explore the further possible biological significance of miR-181a in tumorigenesis. To explore whether miR-181a were associated with several clinicopathologic parameters, the expression of miR-181a in 43 patients treated without neoadjuvant therapy were detected. The clinical and pathological characteristics of these patients are summarized in Table 2. Detailed backgrounds for each patient, including age, histology, clinical staging, tumor diameter, lymph node, expression levels of Her-2 and Ki-67 have been collected. Analysis of these data showed that there was no association between the clinicopathological features and miR-181a (\( p > 0.05 \), Table 2).

Negative Correlation Expression of miR-181a and Bcl-2 in MCF-7 and MCF-7/ADR Breast Cancer Cells

MCF-7 and MCF-7/ADR cells were exposed to ADR at different concentrations for 48 hours. As shown in Fig. 1A, the half maximal inhibitory concentration (IC\(_{50}\)) of ADR in MCF-7 and MCF-7/ADR cells was 0.36±0.013 and 64.07±2.074 mg/L, respectively (mean±SD; Kruskal-Wallis test; \( p < 0.05 \)). (B,C) The relative expression levels of miR-181a and Bcl-2 mRNA were performed by qRT-PCR in MCF-7 and MCF-7/ADR (Kruskal-Wallis test; \( p < 0.05 \)). (D) Compared to MCF-7 cells, Bcl-2 protein expression was markably increased in MCF-7/ADR. All experiments were performed in triplicate.
The alteration of miR-181a expression involved in chemosensitization to Adriamycin

To determine the effect of miR-181a expression on chemosensitivity to Adriamycin-based chemotherapy, miR-181 mimic or miR-181a inhibitor or miR negative control were successfully transfected into MCF-7 and MCF-7/ADR cells. At 48 hours after transfection, expression of miR-181a was determined by quantitative RT-PCR assay (Fig. 2A). Detected by cck-8 assay, transfection with the miR-181a inhibitor reduced susceptibility to ADR. Conversely, cells transfected with miR-181a mimic showed the effect of chemosensitization (Fig. 2B, 2C).

Bcl-2 is required for the effect of miR-181a on chemosensitivity

To investigate whether Bcl-2 directly regulates chemosensitivity to Adriamycin, Bcl-2 siRNA was transfected into MCF-7 and MCF-7/ADR cell lines. The results showed that genetic knockout of Bcl-2 attenuated resistance to ADR in both cell lines.
In MCF-7 and MCF-7/ADR cells transfected with Bcl-2 siRNA, the IC50 value were 0.21±0.04 mg/l and 44.39±1.65 mg/l (mean±SD), respectively (p<0.05) (Fig. 3A). Compared with cells transfected with Bcl-2 siRNA only, the alteration of miR-181a expression didn’t obviously enhance or reduce the chemosensitivity to adriamycin in MCF-7 and MCF-7/ADR cells transfected with Bcl-2 siRNA and miR-181a mimic/inhibitor (p>0.05) (Fig. 3B, 3C).

Downregulation of miR-181a decreased adriamycin-induced apoptosis of MCF-7 and MCF-7/ADR

Compared with the negative controls, the apoptosis rate was significantly increased in MCF-7 and MCF-7/ADR cells transfected with miR-181a mimic [Fig. 4A; apoptosis rate in MCF-7/ADR cells: control, 5.3%±0.41% vs. mimic, 9.7%±1.17% (p<0.05) vs. control mimic+ADR, 15.2%±0.93% (p<0.05) vs. mimic+ADR, 27.7%±1.30% (p<0.05), mean±SD]. Furthermore, downregulation of endogenous miR-181a inhibited ADR-induced apoptosis in cells [Fig. 4B; apoptosis rate in MCF-7 cells: control, 4.9%±0.33% vs. inhibitor, 1.7%±0.40% (p<0.05) vs. control inhibitor+ADR, 15.1%±1.92% (p<0.05) vs. inhibitor+ADR, 4.8%±0.67% (p<0.05), mean±SD].

Evidence of inverse regulation of Bcl-2 by miR-181a

To understand the mechanism by which miR-181a modulated chemosensitivity of MCF-7 cell line, two prediction algorithms, TargetScan and miRecord, were utilized to identify the
potential target gene. Bcl-2, whose gene product is known to have a role in reducing apoptosis, was one of the possible target genes of miR-181a. Thus, qRT-PCR and Western blot were performed to test whether expression of Bcl-2 could be altered by miR-181a. As shown in Fig. 5A, the assay revealed that the decreased expression of Bcl-2 mRNA in MCF-7 cells was altered...
Zhu et al.: The Function Role of miR-181a in Breast Cancer Cells

Cellular Physiology and Biochemistry

by the overexpression of miR-181a [untreated cell, 1-fold vs. mimic, 0.66-fold±0.12 (p=0.000) vs. control mimic, 1.01-fold±0.04 vs. inhibitor, 1.71-fold±0.28 (p=0.000) vs. control inhibitor, 1.00-fold±0.02, mean±SD] and transfected with miR-181a inhibitor increased the expression of Bcl-2 mRNA and protein levels in both MFC-7 and MCF-7/ADR. Meanwhile, transfected with miR-181a mimic in MCF-7 and MCF-7/ADR cells resulted in a significant reduction of Bcl-2 expression both in mRNA and protein expression (A,B,C).

Computational analysis informed that there was a binding site on the 3'UTR of the Bcl-2 for miR-181a, which was highly conserved in mammals. To ascertain whether these miR-181a-binding sequences directly contributed to the negative regulation of Bcl-2 expression, we explored the effects of miR-181a on activity of the target gene using the vectors that either contained wild-type or mutant miR-181a-binding sequences. As shown in Fig. 6, miR-181a repressed the activity of luciferase fused to the WT Bcl-2 3'UTR, resulting in a 45% reduction (Kruskal-wallis test; p<0.05), while it failed to repress the mutated one (Kruskal-wallis test; p>0.05). Data are representative of three independent experiments.

Fig. 5. The expression of Bcl-2 mRNA and protein levels in MCF-7 and MCF-7/ADR cell lines transfected with miR-181a mimic or inhibitor. (A,B,C) The miR-181a inhibitor increased the expression of Bcl-2 mRNA and protein levels in both MFC-7 and MCF-7/ADR. Meanwhile, transfected with miR-181a mimic in MCF-7 and MCF-7/ADR cells resulted in a significant reduction of Bcl-2 expression both in mRNA and protein expression (A,B,C).

Fig. 6. miR-181a inversely regulates the expression of Bcl-2 via targeting its 3'-UTR. (A) The schematic representation of the PGL3-Bcl-2 3'UTR-WT vector and the complementary site of miR-181a in Bcl-2 3'UTR highlighted in white. (B) Compared to the negative control, miR-181a repressed the activity of luciferase fused to the WT Bcl-2 3'UTR, resulting in a 45% reduction (Kruskal-wallis test; p<0.05), while it failed to repress the mutated one (Kruskal-wallis test; p>0.05). Data are representative of three independent experiments.
miR-181a and Bcl-2 mRNA expression in Breast Cancer Patients with Adriamycin-based Neoadjuvant Chemotherapy

For further evaluate the correlation between the expression of miR-181a and Bcl-2 mRNA in Breast Cancer patients, 35 selected patients with neoadjuvant chemotherapy were classified into responders (n=19) and non-responders (n=16) according to RECIST criteria. Three patients with a complete response (CR) and sixteen patients with a partial response (PR) were regarded as clinical responders. Eight patients had progressive disease (PD), and eight patients had stable disease (SD). Those with SD or PD were deemed to be non-responders. The expression of MDR1 mRNA should be detected by qRT-PCR in the non-responders and responders. The MDR1 mRNA expression was significantly elevated in non-responders (n=16) (Fig. 7A; non-responders vs. responders: 4.10±1.28 vs. 9.07±1.52, mean±SD, p<0.05; two-tailed). To verify the hypothesis that there is a potential relevance between the expression of miR-181a and chemosensitivity, miR-181a and Bcl-2 mRNA expression was evaluated by qRT-PCR in 35 breast tumors. Consequently, linear regression analysis was used to reveal that miR-181a expression was down-regulated in non-responders group (p<0.05; Fig. 7B), with a inverse correlation with Bcl-2 mRNA expression (Spearman rank test; rho=-0.81; p<0.05; Fig. 7C, 7D). Considering the well-characterized role of Bcl-2 in anti-apoptosis, it suggested that in some case, miR-181a play a role in poor response to adriamycin-based neoadjuvant chemotherapy in breast cancer patients via targeting Bcl-2.
**Discussion**

miR-181a is one of the crucial means important microRNAs in cellular differentiation and development, evidenced by its dysregulation in autoimmunity and cancers [19, 20]. It widely exists in human organs, with its highest abundance in brain, liver and eyes during early development [21]. miR-181a was also abundantly expressed in the T lymphocyte and B lymphoid cell [22]. It is still controversial that miR-181a acts as a oncomir or a tumor suppressor. The global downregulation of miR-181a was observed in most solid tumors [17, 18, 23-26] and chronic lymphocytic leukaemia (CLL) [27]. On the contrary, the role of miR-181a in breast cancer was confirmed recently. It was documented that the upregulation of miR-181a might contribute to the development of cancer stem cell properties to promote the metastasis and invasion [28].

The miR-181 family consists of four members (miR-181a,b,c,d) whose seed region is complementary to a large range of identified mRNAs. miR-181a is able to modulate its target genes by inhibitory binding or accelerating degradation of mRNA [29]. Bcl-2, as one of its target mRNAs, inhibits mitochondrial metabolism and adriamycin-induced apoptosis in MCF-7 cells. It might prevent the early apoptotic events and revealed post-mitotic multinucleation without affecting cell cycle arrest [30, 31]. Once the withdrawal, Bcl-2 protein could enhance the capacity of proliferation in tumor cells [15]. In the our study, we identified that the level of miR-181a expression in MCF-7/ADR cells was significantly lower than that in MCF-7 cells by qRT-PCR. The results also showed that genetic knockout of Bcl-2 attenuated resistance to ADR in both cell lines, miR-181a regulated the chemosensitivity to adriamycin mainly through Bcl-2 in MCF-7 and MCF-7/ADR cells. To further investigated the molecular mechanism of how miR-181a involoved in chemosensitivity to ADR in MCF-7 and MCF-7/ADR cells, we transfected cells with miR-181a mimic or inhibitor. The results showed that downregulation of miR-181a reduced susceptibility to ADR and inhibited ADR-induced apoptosis in cells. On the contrary, miR-181a mimic could enhance apoptosis of ADR-induced MCF-7/ADR cells detected by flow cytometry. Moreover, dual luciferase activity assay was performed to determine that overexpression of miR-181a suppressed Bcl-2 gene through binding to motifs in the 3'UTR complementary to the seed region. Concurrent with poor response to ADR, decreased miR-181a and aberrant upregulation of Bcl-2 mRNA were observed in non-responders group, compared with the 19 responders. These data indicated that miR-181a may serve as a potential biomarker to predict the response to ADR-based neoadjuvant chemotherapy. Our conclusion is supported by both vitro and clinical investigation.

Prior to neoadjuvant chemotherapy, all patients received core needle biopsy to confirm the nature and pathological type of breast tumor. In the future, based on our findings, we could detect the expression of miR-181a in biopsy specimens to speculate the effect of ADR-based neoadjuvant chemotherapy. Our study provided a theoretical basis for the choice of medicine.

Additionally, we demonstrated that there was no association between the clinicopathological features and miR-181a. In a recent study by Yang et al. [32], patients with higher level of miR-181a was more likely to have lymph node metastases. This discrepancy may be due to cell type-specific response to miR-181a. It is advisable to regard its function in a complete setting that is the context in which it is undertaking.

However, the exact mechanism in mediating tumor cells response to chemotherapy is still unknown. We discovered that MDR1 mRNA detected by qRT-PCR was generally elevated in those patients which were classified into non-responders. These data of MDR1 were also in agreement with our classification according to the CT tests and detection of serum tumor marker. As a bold assumption, miR-181a may also have an intersecting complex effect that spans a multiplicity of drug-resistance pathways and processes. It needs to be further investigated.

In summary, the study first identified that there was a causal correlation between overexpression of miR-181a and chemosensitivity to adriamycin in both vitro and NAC.
patients via targeting Bcl-2. According to the level of miR-181a, we may evaluate whether the patient is sensitive to ADR-based neoadjuvant chemotherapy. It may direct the clinical medication. miR-181a-based therapy may serve as a highly promising option for patients with poor-response to adriamycin because of its enhanced adriamycin-induced apoptosis. Owing to the complex networks among miR-181a and its targets, a better understanding of miRNA-based therapy requires further investigation before designing safe procedure.

**Conflict of Interests**

The authors have declared that no competing interests exist.

**Acknowledgements**

This work was supported by grants from the National Natural Science Foundation of China (81272470). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Reference**

Zhu et al.: The Function Role of miR-181a in Breast Cancer Cells


26 Gao W, Yu Y, Cao H, Shen H, Li X, Pan S, Shu Y: Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 2010;64:399-408.


